Alnylam's Record Quarter Fails to Boost Valuation
Despite achieving its best quarter ever with over $1 billion in product revenue, Alnylam Pharmaceuticals (NASDAQ:ALNY) has not seen a corresponding rise in valuation. The company reported net product revenue of $1.036 billion for Q1 2026, up 121% year-over-year and driven largely by its TTR franchise, which generated $910 million from AMVUTTRA and ONPATTRO combined. The biotech sector as a whole is experiencing a resurgence in venture funding and IPO activity. In the first half of 2026 alone, biotech startups raised over $9 billion, with 13 IPOs raising nearly $4.5 billion collectively. Alnylam's profitability has also improved dramatically; it turned from a GAAP loss to net income of $206 million in Q1 compared to the same period last year. However, despite these strong fundamentals and durable growth across multiple products, Alnylam’s forward P/E ratio remains at around 32.5x—lower than its historical highs during early profitability phases. Institutional ownership has slightly declined from previous quarters, with short interest representing about 4.36% of the public float.
Tickers: $ALNY
Topics: biotech market valuation revenue growth RNAi therapies